Home / Business and Economy / Eli Lilly Launches Mounjaro Injector Pen in India, Challenges Novo Nordisk
Eli Lilly Launches Mounjaro Injector Pen in India, Challenges Novo Nordisk
25 Aug
Summary
- Eli Lilly launches easy-to-use Mounjaro injector pen in India
- Mounjaro competes with Novo Nordisk's Wegovy weight-loss drug
- Mounjaro more expensive than cheaper generic versions in India
On August 13, 2025, Eli Lilly and Company launched the easy-to-use injector pen version of its weight-loss and diabetes drug, Mounjaro, in India. This launch comes two months after Eli Lilly's rival, Novo Nordisk, released its weight-loss drug Wegovy in the country.
The launch of the Mounjaro injector pen is significant as it makes the drug much easier to administer, which is crucial in a market like India that is seeing an increasing number of obesity and type 2 diabetes cases. Eli Lilly had initially launched Mounjaro in India in March 2025, but it was only available through vials.
However, Eli Lilly faces stiff competition not only from Wegovy but also from cheaper generic versions of the drugs that are made in India. This makes Mounjaro more expensive, relatively speaking, for the generally price-sensitive Indian consumers.
Despite this challenge, Wall Street remains bullish on Eli Lilly's stock, with an average "Buy" rating and an average implied upside of 28.17%. While the company's Mounjaro launch in India is a positive development, some analysts believe that certain AI stocks may offer greater upside potential and carry less downside risk for investors.
